Citigroup Cuts Structure Therapeutics (NASDAQ:GPCR) Price Target to $97.00

Structure Therapeutics (NASDAQ:GPCR) had its price target dropped by research analysts at Citigroup from $100.00 to $97.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s target price suggests a potential upside of 82.54% from the company’s current price.

GPCR has been the subject of a number of other reports. Citizens Jmp reduced their target price on shares of Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating for the company in a research note on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Wall Street Zen raised shares of Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Canaccord Genuity Group set a $111.00 target price on shares of Structure Therapeutics in a report on Friday. Finally, HC Wainwright decreased their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Structure Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $110.91.

Structure Therapeutics Stock Performance

GPCR stock traded up $0.52 during mid-day trading on Friday, hitting $53.14. 328,648 shares of the company were exchanged, compared to its average volume of 893,274. Structure Therapeutics has a 1-year low of $15.86 and a 1-year high of $94.90. The firm’s 50 day simple moving average is $47.36 and its 200 day simple moving average is $54.20. The firm has a market cap of $3.78 billion, a P/E ratio of -61.08 and a beta of -1.43.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, equities research analysts predict that Structure Therapeutics will post -1.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in GPCR. Handelsbanken Fonder AB acquired a new stake in shares of Structure Therapeutics in the 2nd quarter valued at approximately $1,041,000. Seven Fleet Capital Management LP acquired a new position in Structure Therapeutics during the first quarter worth $434,000. Avidity Partners Management LP bought a new stake in Structure Therapeutics during the first quarter worth $1,446,000. Bank of America Corp DE lifted its stake in Structure Therapeutics by 617.0% in the first quarter. Bank of America Corp DE now owns 227,132 shares of the company’s stock valued at $10,948,000 after acquiring an additional 195,454 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Structure Therapeutics by 5.2% in the first quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock valued at $258,260,000 after acquiring an additional 264,833 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.